Q3 2021 Investor Relations Results
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
Sandoz performance ex-US normalizing, growing +3% in Q3
1 GROWTH
Q3: Biosimilars, Retail in Europe
and ROW gaining share
Q3 sales USD 2.4bn (-2% cc)
Europe +2% (56% of sales)
Bio, Retail, gaining market share
■ ROW +6% (26% of sales)
Steady growth across regions,
Biosimilars and Retail
■ US -20% (18% of sales)
Price erosion, contract terminations
Q3 Core Opinc 0.6bn (-15%)
Unfavorable gross margin in US
Q4: Performance normalizing ex-US
as COVID-19 impact decreases
Direct demand
■ Different business segments normalizing
at different rates
■ Demand impact in Q4 expected to be
in line with Q3
Cough & Cold
■ Could start to return to pre-Covid levels
in several markets
Losartan
Negative impact of recall
All growth rates in constant currencies unless otherwise stated STO Sandoz Technical Operations
11 Investor Relations | Q3 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation